AstraZeneca AB (manufacturing, quality control, batch release, primary and secondary packaging)

Ukraine

All drugs from this manufacturer

  • TAGRISSO

    The drug is used for the treatment of adult patients with non-small cell lung cancer (NSCLC) harboring specific EGFR receptor mutations (specifically exon 19 deletions, L858R substitution, or the T790M mutation). It is used both after tumor removal surgery (adjuvant therapy) and for the treatment of locally advanced or metastatic cancer.

    Dosage form: tablets, film-coated

    Active substance Dosage
    osimertinib 40 mg

    ATC: L01EB04

  • TAGRISSO

    The drug is used for the treatment of adult patients with non-small cell lung cancer (NSCLC) harboring certain EGFR gene mutations. It is used both after tumor removal surgery (adjuvant therapy) and for the treatment of locally advanced or metastatic cancer.

    Dosage form: tablets, film-coated

    Active substance Dosage
    osimertinib 80 mg

    ATC: L01EB04